STOCK TITAN

Vanguard realigns reporting; Vanguard (LH) amendment shows 0 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed an amendment to Schedule 13G reporting that it beneficially owns 0 shares of Labcorp Holdings Inc Common Stock and holds 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain subsidiaries or business divisions to report disaggregated ownership separately from The Vanguard Group.

The form states The Vanguard Group and its managed accounts have the right to receive dividends or proceeds for the securities reported, and no single other person holds more than 5% of the class according to the filing. The submission is signed by the Head of Global Fund Administration on 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment shows disaggregation after Vanguard internal realignment; beneficial ownership is zero.

The filing records 0 shares beneficially owned and 0% of the class, and cites SEC Release No. 34-39538 describing separate reporting by subsidiaries and business divisions after an internal realignment on January 12, 2026. This explains the change in disclosure structure rather than an active buy/sell.

Cash-flow treatment or trading activity is not described in the excerpt; subsequent filings from the named subsidiaries would show any holdings. Future Schedule 13 filings from those entities will clarify where economic ownership now appears.

Amendment is procedural and reconciles reporting after corporate reorganization.

The text references reliance on SEC Release No. 34-39538 to disaggregate beneficial ownership among Vanguard affiliates following internal realignment. The filing explicitly states no single other person has >5% ownership and that Vanguard-managed accounts retain dividend/proceeds rights.

From a compliance view, this amendment aligns public records with internal account structures; it does not assert any new aggregate stake in the issuer within this filing.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does the Schedule 13G/A for LH filed by The Vanguard Group state?

The filing states The Vanguard Group beneficially owns 0 shares of Labcorp Holdings Inc and reports 0% ownership, with signature dated 03/26/2026. It explains this follows an internal realignment under SEC Release No. 34-39538.

Why does Vanguard report zero beneficial ownership in the amendment?

Vanguard says an internal realignment on January 12, 2026 caused subsidiaries/divisions to report ownership separately under SEC Release No. 34-39538, resulting in The Vanguard Group itself reporting 0 shares for this filing.

Does the filing say who now reports the Labcorp shares previously tied to Vanguard?

The amendment states subsidiaries or business divisions will report disaggregated ownership separately; it does not name those specific reporting entities in this excerpt or provide their share counts.

Does anyone else hold more than 5% of Labcorp according to this filing?

The filing indicates that no one other person's interest in the securities reported here is more than 5%; the Vanguard Group and managed accounts retain dividend/proceeds rights as described.

Who signed the Schedule 13G/A amendment for The Vanguard Group?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with the signature date of 03/26/2026.
Labcorp Holdings Inc

NYSE:LH

View LH Stock Overview

LH Rankings

LH Latest News

LH Latest SEC Filings

LH Stock Data

21.92B
82.07M
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON